News › Clinical Practice, Industry News, Patient Care

A Novel Formulation for Investigational Botulinum Toxin A

October 22, 2019

Swiss healthcare company Galderma has announced the phase 2 clinical trial results for its liquid formulation of investigational botulinum toxin, QM1114. The study—conducted as multi-center, randomized, double-blind and placebo-controlled—successfully showcased the safety and efficacy of botulinum toxin type A, according to the company.
“Toxin treatment-naive subjects aged ≥18 years with moderate-to-very severe GLs [glabellar lines] at maximum frown and at least mild GLs at rest were eligible for this multi-centre, double-blind 6-month Phase II study,” according to the abstract from the oral presentation on the subject at the 24th World Congress of Dermatology, Milan.
Read more at Dermatology Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AmSpa CEO Reflects on the Sonya Dakar Case
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • PDGF, Regenerative Medicine and the Questions Med Spas Can’t Ignore
    • Medicare GLP-1 Bridge Program Launches July 1, Expanding Access for Some Patients
Advertisement